Predictive Biomarkers of Immune Checkpoint Inhibition in Gastroesophageal Cancers.

Abstract

Immune checkpoint inhibition has transformed cancer treatment. For gastroesophageal cancer, this class of drugs have demonstrated durable responses and survival benefit in a subgroup of patients, resulting in regulatory approval. However, several recent randomized phase III studies in gastroesophageal cancer have reported negative results, blunting initial enthusiasm. Identification and validation of predictive biomarkers with appropriate patient selection for benefit from immunotherapy is an area of intense research with novel concepts rapidly emerging. In this review we describe the latest immune checkpoint inhibitor trials which have been reported in gastroesophageal cancers with a focus on predictive biomarkers. We also explore novel biomarkers being developed to improve precision oncology for immunotherapy in gastroesophageal cancers.

• Authors: Raghav Sundar, Elizabeth C Smyth, Siyu Peng, Joe P S Yeong, Patrick Tan
• Journal: Frontiers in oncology (Front Oncol) Vol. 10 Pg. 763 ( 2020) ISSN: 2234-943X [Print] Switzerland
• PMID: 32500029 (Publication Type: Journal Article, Review)
• Copyright: Copyright © 2020 Sundar, Smyth, Peng, Yeong and Tan.